Expand VNDA Menu
VNDA MENU

VNDA Latest Press Releases

-- July 29, 2026 --

Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026 PRNewswire 4:32 PM

-- July 16, 2026 --

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe PRNewswire 4:30 PM

-- July 15, 2026 --

NEREUS Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment PRNewswire 4:30 PM

-- July 10, 2026 --

Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit PRNewswire 4:30 PM

-- July 7, 2026 --

Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S PRNewswire 4:31 PM

-- May 27, 2026 --

Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis PRNewswire 7:00 AM

-- May 7, 2026 --

Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences PRNewswire 6:44 PM

-- May 1, 2026 --

Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years PRNewswire 4:36 PM

-- April 29, 2026 --

Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 PRNewswire 4:30 PM

-- April 28, 2026 --

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence PRNewswire 7:13 PM

-- April 22, 2026 --

Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors PRNewswire 5:14 PM

-- April 9, 2026 --

Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines PRNewswire 11:03 AM

-- April 8, 2026 --

Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists PRNewswire 4:56 PM

-- March 19, 2026 --

Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods PRNewswire 4:35 PM

-- March 3, 2026 --

Vanda Announces FDA Grants Landmark Hearing for HETLIOZ in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years PRNewswire 8:02 AM
Market Data Delayed 15 Minutes